Has Kim Kardashian confirmed using Ozempic?

No. Kim Kardashian has not publicly confirmed or denied using Ozempic or any GLP-1 receptor agonist. The association between Kardashian and Ozempic is based entirely on public speculation following her documented weight loss before the 2022 Met Gala. She attributed that weight loss to diet and exercise changes.

How much weight do people regain after stopping semaglutide?

The STEP 1 extension trial found that participants regained approximately two-thirds of the weight they had lost within one year of stopping semaglutide 2.4 mg. This regain was accompanied by partial reversal of improvements in blood pressure, waist circumference, and lipid levels.

Is Ozempic meant to be taken forever?

Wegovy (the obesity-indication formulation of semaglutide) carries FDA labeling for "chronic weight management," which implies ongoing use. Clinical trial data consistently show that weight regain occurs after discontinuation. Whether a specific patient stays on treatment indefinitely depends on individual risk-benefit discussions with their prescriber.

Can diet and exercise prevent weight regain after stopping a GLP-1?

Diet and exercise can attenuate weight regain but typically cannot fully prevent it. High-protein diets and resistance training help preserve lean mass, which supports metabolic rate. Published data, including the STEP 1 extension, show that behavioral strategies alone do not replicate the appetite-suppression and metabolic effects of active GLP-1 pharmacotherapy.

Did Kris Jenner confirm using Ozempic?

Kris Jenner has publicly discussed using GLP-1 medications on The Kardashians (Hulu). Her disclosure pertains only to her own medical decisions and does not confirm or imply that other family members, including Kim Kardashian, use the same medications.

Kim Kardashian, Maintenance, and What Happens If You Stop

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Kim Kardashian, Maintenance, and What Happens If You Stop Image: HealthRX.com clinical image

The Public Record: What Kim Kardashian Has (and Hasn't) Said

In May 2022, Kim Kardashian told Vogue she lost 16 pounds in three weeks to fit into Marilyn Monroe's iconic dress for the Met Gala. She described a strict diet of cutting out sugar and carbs, paired with daily exercise. She did not mention any medication.

That timeline, combined with the broader cultural moment around GLP-1 prescriptions in Hollywood, triggered widespread public speculation that Kardashian had used Ozempic (semaglutide). Publications including The New York Post, Page Six, and multiple entertainment outlets amplified the speculation throughout 2022 and 2023.

Kim Kardashian has never publicly confirmed using Ozempic, semaglutide, or any GLP-1 receptor agonist. Any connection between Kardashian and these drugs remains unconfirmed speculation.

Her mother, Kris Jenner, has separately and publicly discussed her own use of GLP-1 medications on The Kardashians (Hulu), which added fuel to public curiosity about the family's relationship with the drug class.

Why Discontinuation Matters, Celebrity or Not

The Kardashian speculation became a cultural inflection point. It pushed Ozempic out of diabetes clinics and into dinner-table conversation. But it also surfaced a question that clinicians were already tracking: if millions of people start GLP-1 receptor agonists for weight management, what happens when they stop?

This is not a hypothetical. Insurance coverage gaps, drug shortages (the FDA listed semaglutide on its shortage database through much of 2023-2024), cost barriers, and side-effect intolerance all create real-world discontinuation scenarios. The clinical literature on this topic is clear, and it is not especially reassuring.

The STEP 1 Extension Trial: A Year After Stopping

The most cited data on GLP-1 discontinuation comes from the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022. Participants who lost an average of 17.3% of body weight on semaglutide 2.4 mg over 68 weeks were followed for an additional year after drug withdrawal.

The findings were stark. Within one year of stopping semaglutide:

Participants regained approximately two-thirds of their prior weight loss.
Mean weight change from the end of treatment to week 120 was +11.6 percentage points of body weight regained.
Cardiometabolic improvements (waist circumference, blood pressure, lipid profiles) also partially reversed.

This was not a failure of willpower. The regain pattern reflects the biology of GLP-1 receptor agonism and what happens when that pharmacological signal is removed.

The Biology of Rebound: Why Weight Returns

GLP-1 receptor agonists like semaglutide work through multiple mechanisms simultaneously. They slow gastric emptying, reduce appetite signaling in the hypothalamus, and appear to alter food reward pathways in the brain. When the drug is withdrawn, those effects reverse.

Appetite rebounds. Semaglutide suppresses hunger through central nervous system GLP-1 receptor activation. Once the drug clears (semaglutide has a half-life of roughly one week), appetite returns to pre-treatment levels or, in some patients, temporarily exceeds them. A 2023 analysis in The Lancet noted that subjective hunger scores returned to baseline within weeks of discontinuation.

Metabolic adaptation persists. Weight loss itself triggers compensatory metabolic changes: reduced resting energy expenditure, altered thyroid hormone signaling, and shifts in leptin and ghrelin. These adaptations, sometimes called "metabolic adaptation," were documented in a 2016 Obesity study and do not resolve simply because a patient loses weight pharmacologically rather than through caloric restriction alone.

Gastric emptying normalizes. The delayed gastric emptying that makes patients feel full faster on semaglutide reverses after discontinuation, per data from clinical pharmacology studies filed with the FDA. Patients report feeling less satiated by the same meals they tolerated easily while on treatment.

What "Long-Term Use" Actually Means for GLP-1s

The FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in June 2021. The word "chronic" is doing significant work in that label. It signals what the clinical evidence supports: GLP-1 receptor agonists for obesity function more like blood pressure medication than like a course of antibiotics. The condition they treat (excess adiposity and its metabolic consequences) is ongoing.

The SELECT trial, published in The New England Journal of Medicine in 2023, demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg over a mean follow-up of 39.8 months. Those cardiovascular benefits were sustained only while patients remained on treatment.

This creates a tension that no celebrity headline captures well. Stopping a GLP-1 is not the same as "finishing" treatment. In clinical terms, discontinuation of an effective GLP-1 RA in a patient with obesity is closer to discontinuing a statin in a patient with hyperlipidemia: the underlying condition and its risks return.

At a glance

Kim Kardashian's connection to Ozempic is publicly speculated, not confirmed. She has never stated she uses or has used the drug.
The STEP 1 extension showed ~67% weight regain within one year of stopping semaglutide 2.4 mg.
Appetite, gastric motility, and metabolic rate all revert toward baseline after GLP-1 discontinuation.
FDA labeling for Wegovy uses the word "chronic," meaning the drug is designed for ongoing use, not short courses.
Cardiovascular benefits from SELECT trial were sustained only during active treatment.
Kris Jenner has publicly discussed GLP-1 use, but this does not confirm use by other family members.

The HealthRX.com Medical Team Take

The speculation around Kim Kardashian and Ozempic, whether it reflects reality or not, exposed a gap in public understanding about GLP-1 medications. The framing was almost always cosmetic: "Did she or didn't she?" The more useful question, the one that actually affects the millions of patients prescribed these drugs, is about duration and discontinuation.

The HealthRX.com Medical Team sees three clinical realities that get lost in celebrity discourse:

First, GLP-1 receptor agonists treat a chronic disease. Obesity meets every criterion for a chronic medical condition. Treating it with a short course of medication and expecting permanent results is like treating hypertension with three months of lisinopril and hoping blood pressure stays down. The biology does not work that way.

Second, discontinuation planning should start before prescribing. If a patient cannot access semaglutide long-term (whether due to cost, insurance, or personal preference), that should shape the initial treatment conversation. A 2024 consensus statement from the Endocrine Society recommends discussing maintenance strategy, including the likelihood of weight regain, before initiating any anti-obesity medication.

Third, weight regain after GLP-1 discontinuation is not a character flaw. It is a predicted pharmacological outcome supported by every major discontinuation dataset published to date. The STEP 1 extension, the STEP 4 trial (which studied treatment withdrawal at week 20), and real-world registry data all converge on the same conclusion: removing the drug removes its effect.

For patients who do discontinue, the evidence supports a structured transition. High protein intake (1.2 to 1.6 g/kg/day per AHA dietary recommendations), resistance training to preserve lean mass, and close metabolic monitoring during the first 6 to 12 months off treatment represent the best available approach to attenuating regain, though none of these measures fully replaces the pharmacological effect.

What the Data Say About Maintenance Strategies

For patients who remain on GLP-1 therapy long-term, the evidence is more encouraging. The STEP 5 trial followed patients on semaglutide 2.4 mg for two full years and found sustained weight loss of approximately 15.2% from baseline, with continued metabolic benefits.

Dose adjustments represent another real-world pattern. Some clinicians step patients down to lower maintenance doses (1.0 mg or 1.7 mg weekly) after reaching target weight, though this approach lacks the randomized trial data that the full 2.4 mg dose carries. The HealthRX.com Medical Team notes that this is a common clinical practice, but patients considering it should be aware that lower doses produce less appetite suppression and may result in partial weight regain.

Combination approaches are also under study. Tirzepatide (a dual GIP/GLP-1 agonist) has shown greater weight loss in head-to-head comparisons with semaglutide, raising questions about whether switching agents could improve maintenance for patients with inadequate response. The HealthRX.com Medical Team cautions that the discontinuation biology likely applies equally to tirzepatide, as preliminary withdrawal data from the SURMOUNT-4 trial show similar regain patterns.

Frequently asked questions

›

References

Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022. PubMed
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023. NEJM
Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021. PubMed
Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022. PubMed
Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024. PubMed
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018. PubMed
Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016. PubMed
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed
FDA. Wegovy approval press announcement. June 2021. FDA.gov
FDA Drug Shortages Database. AccessData
Endocrine Society. Clinical practice guideline: pharmacological management of obesity. 2024. Endocrine.org